Featured Research

from universities, journals, and other organizations

Engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice

Date:
August 8, 2011
Source:
University of Pennsylvania School of Medicine
Summary:
Medical researchers have shown for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice. Ovarian cancer is the most lethal reproductive cancer for women, with one-fifth of women diagnosed with advanced disease surviving five years. Nearly all ovarian cancers (90%) are characterized by their expression of a distinct cell-surface protein called alpha-folate receptor, which can be a target for engineered T cells.

In a past clinical study, first generation engineered T cells did not shrink tumors in women with ovarian cancer because the T cells did not persist in the patients. The new second generation technology developed in the current study overcomes the limitations of the first generation approach. Here, second generation T cells shrank tumors; whereas, T cells engineered using first generation technology did not.

The alpha-folate receptor is expressed on the surface of ovarian cancer cells and has a high affinity for folic acid, a vitamin which helps "feed" the cancer cells, and represents an "Achilles' Heel" for cancer researchers to target.

"We anticipate the opening of a genetically modified T cell clinical trial in the next few months for women with recurrent ovarian cancer," says Powell. "Targeting the alpha-folate receptor is an opportunity for widespread clinical application."

Until now, human T cells engineered to express an antibody fragment specific for the alpha-folate receptor protein have shown anti-tumor activity against epithelial cancers in the lab, but not in the clinic due to their inability to persist and home to tumors in the human body. The modified T cells used in this study express an engineered fusion protein -- called a chimeric antigen receptor -- that combines the specificity of an antibody with the T cell signaling portions from two different proteins that stimulate the immune system to recognize ovarian cancer cells. These added signaling protein pieces give the engineered T cells the extra survival signals they need to do their job.

Two Birds, One Stone T Cells

The double-barreled cells are engineered to multiply, survive, recognize, and kill ovarian tumors. The modified T cells are expanded for two weeks in the lab, and then tested for reactivity by exposing them to human ovarian cancer cells to see if they destroy the cancer cells. Researchers also test for effectiveness by measuring cytokine production by the T cells, a sign of inflammation produced by the engineered T cells when killing cancer cells.

The new second generation engineered cells were successful in many ways. They were resistant to cancer-induced cell death: Fewer new T cells died when exposed to cancer cells, compared to the older technology. The new T cells also multiply better and survive; therefore their numbers increase over time in test-tube experiments and in the mouse model.

A clinical trial using these T cells is pending with George Coukos, MD, Director of the Ovarian Cancer Research Center at Penn and the trial's principal investigator. Penn is the only study site identified to date. Investigators aim to recruit up to 21 patients with advanced recurrent ovarian cancer whose tumors express the alpha-folate receptor.

"This technology represents a promising advancement for the treatment of women with ovarian cancer," Powell says, "But we will continue to work around the clock to improve this approach using other costimulatory portions and antibody-like proteins to make this the most powerful and safe approach for the treatment of the greatest number of women with this horrible disease."


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. D.-G. Song, Q. Ye, C. Carpenito, M. Poussin, L.-P. Wang, C. Ji, M. Figini, C. H. June, G. Coukos, D. J. Powell. In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). Cancer Research, 2011; 71 (13): 4617 DOI: 10.1158/0008-5472.CAN-11-0422

Cite This Page:

University of Pennsylvania School of Medicine. "Engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice." ScienceDaily. ScienceDaily, 8 August 2011. <www.sciencedaily.com/releases/2011/08/110808115412.htm>.
University of Pennsylvania School of Medicine. (2011, August 8). Engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2011/08/110808115412.htm
University of Pennsylvania School of Medicine. "Engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice." ScienceDaily. www.sciencedaily.com/releases/2011/08/110808115412.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins